230 related articles for article (PubMed ID: 31456520)
21. Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer.
Malgerud L; Lindberg J; Wirta V; Gustafsson-Liljefors M; Karimi M; Moro CF; Stecker K; Picker A; Huelsewig C; Stein M; Bohnert R; Del Chiaro M; Haas SL; Heuchel RL; Permert J; Maeurer MJ; Brock S; Verbeke CS; Engstrand L; Jackson DB; Grönberg H; Löhr JM
Mol Oncol; 2017 Oct; 11(10):1413-1429. PubMed ID: 28675654
[TBL] [Abstract][Full Text] [Related]
22. An Inhibitor of the Pleckstrin Homology Domain of CNK1 Selectively Blocks the Growth of Mutant KRAS Cells and Tumors.
Indarte M; Puentes R; Maruggi M; Ihle NT; Grandjean G; Scott M; Ahmed Z; Meuillet EJ; Zang S; Lemos R; Du-Cuny L; Layng FIAL; Correa RG; Bankston LA; Liddington RC; Kirkpatrick L; Powis G
Cancer Res; 2019 Jun; 79(12):3100-3111. PubMed ID: 31040156
[TBL] [Abstract][Full Text] [Related]
23. Detection of KRAS Mutations in Circulating Tumor DNA by Digital PCR in Early Stages of Pancreatic Cancer.
Brychta N; Krahn T; von Ahsen O
Clin Chem; 2016 Nov; 62(11):1482-1491. PubMed ID: 27591291
[TBL] [Abstract][Full Text] [Related]
24. Challenges in Ras therapeutics in pancreatic cancer.
Choi M; Bien H; Mofunanya A; Powers S
Semin Cancer Biol; 2019 Feb; 54():101-108. PubMed ID: 29170065
[TBL] [Abstract][Full Text] [Related]
25. [Prognostic value of important driver gene mutations in patients with radical resection of pancreatic cancer].
Shen J; Gao SZ; Wang H; Shi XH; Li B; Pan YQ; Shen S; Shao Z; Guo SW; Jin G
Zhonghua Wai Ke Za Zhi; 2019 Nov; 57(11):840-847. PubMed ID: 31694133
[No Abstract] [Full Text] [Related]
26. Progression of Chronic Pancreatitis to Pancreatic Cancer: Is There a Role of Gene Mutations as a Screening Tool?
Rashid S; Singh N; Gupta S; Rashid S; Nalika N; Sachdev V; Bal CS; Datta Gupta S; Chauhan SS; Saraya A
Pancreas; 2018 Feb; 47(2):227-232. PubMed ID: 29303908
[TBL] [Abstract][Full Text] [Related]
27. Case Report: Anlotinib combined with PD-1 inhibitor and sequential GA regimen or FOLFIRINOX Chemotherapy in treatment of KRAS G12V mutated pancreatic ductal adenocarcinoma with liver metastasis: A case and literature review.
Wang Y; Wang B; Xiang L; Deng J; Xu B; He P; Pu W; Wang H; Fan Y; Chen H
Front Immunol; 2022; 13():1016647. PubMed ID: 36311715
[TBL] [Abstract][Full Text] [Related]
28. [KRAS mutation assay on EUS-FNA specimens from pacients with pancreatic mass].
Bunganič B; Hálková T; Benešová L; Belšánová B; Laclav M; Hrůzová M; Traboulsi E; Frič P; Suchánek Š; Minárik M; Zavoral M
Cas Lek Cesk; 2016; 155(1):48-51. PubMed ID: 26898792
[TBL] [Abstract][Full Text] [Related]
29. Sequential Targeting TGF-β Signaling and KRAS Mutation Increases Therapeutic Efficacy in Pancreatic Cancer.
Pei Y; Chen L; Huang Y; Wang J; Feng J; Xu M; Chen Y; Song Q; Jiang G; Gu X; Zhang Q; Gao X; Chen J
Small; 2019 Jun; 15(24):e1900631. PubMed ID: 31033217
[TBL] [Abstract][Full Text] [Related]
30. Constitutively active Akt1 cooperates with KRas(G12D) to accelerate in vivo pancreatic tumor onset and progression.
Albury TM; Pandey V; Gitto SB; Dominguez L; Spinel LP; Talarchek J; Klein-Szanto AJ; Testa JR; Altomare DA
Neoplasia; 2015 Feb; 17(2):175-82. PubMed ID: 25748236
[TBL] [Abstract][Full Text] [Related]
31. EGFR High Expression, but not KRAS Status, Predicts Sensitivity of Pancreatic Cancer Cells to Nimotuzumab Treatment In Vivo.
Zhou C; Zhu L; Ji J; Ding F; Wang C; Cai Q; Yu Y; Zhu Z; Zhang J
Curr Cancer Drug Targets; 2017; 17(1):89-97. PubMed ID: 27739365
[TBL] [Abstract][Full Text] [Related]
32. KRAS promotes tumor metastasis and chemoresistance by repressing RKIP via the MAPK-ERK pathway in pancreatic cancer.
Yang K; Li Y; Lian G; Lin H; Shang C; Zeng L; Chen S; Li J; Huang C; Huang K; Chen Y
Int J Cancer; 2018 Jun; 142(11):2323-2334. PubMed ID: 29315556
[TBL] [Abstract][Full Text] [Related]
33. KRAS, BRAF, and PIK3CA mutations, and patient prognosis in 126 pancreatic cancers: pyrosequencing technology and literature review.
Zhou L; Baba Y; Kitano Y; Miyake K; Zhang X; Yamamura K; Kosumi K; Kaida T; Arima K; Taki K; Higashi T; Imai K; Hashimoto D; Yamashita Y; Chikamoto A; Beppu T; Tan X; Baba H
Med Oncol; 2016 Apr; 33(4):32. PubMed ID: 26927447
[TBL] [Abstract][Full Text] [Related]
34. A genetically engineered mouse model developing rapid progressive pancreatic ductal adenocarcinoma.
Yamaguchi T; Ikehara S; Nakanishi H; Ikehara Y
J Pathol; 2014 Oct; 234(2):228-38. PubMed ID: 25042889
[TBL] [Abstract][Full Text] [Related]
35. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets.
Witkiewicz AK; McMillan EA; Balaji U; Baek G; Lin WC; Mansour J; Mollaee M; Wagner KU; Koduru P; Yopp A; Choti MA; Yeo CJ; McCue P; White MA; Knudsen ES
Nat Commun; 2015 Apr; 6():6744. PubMed ID: 25855536
[TBL] [Abstract][Full Text] [Related]
36. Perioperative bevacizumab improves survival following lung metastasectomy for colorectal cancer in patients harbouring v-Ki-ras2 Kirsten rat sarcoma viral oncogene homologue exon 2 codon 12 mutations†.
Renaud S; Schaeffer M; Falcoz PE; Seitlinger J; Romain B; Voegeli AC; Legrain M; Reeb J; Santelmo N; Rohr S; Brigand C; Olland A; Guenot D; Massard G
Eur J Cardiothorac Surg; 2017 Feb; 51(2):255-262. PubMed ID: 28186237
[TBL] [Abstract][Full Text] [Related]
37. Decreased expression of DAB2IP in pancreatic cancer with wild-type KRAS.
Duan YF; Li DF; Liu YH; Mei P; Qin YX; Li LF; Lin QX; Li ZJ
Hepatobiliary Pancreat Dis Int; 2013 Apr; 12(2):204-9. PubMed ID: 23558076
[TBL] [Abstract][Full Text] [Related]
38. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
[TBL] [Abstract][Full Text] [Related]
39. Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients.
Kim D; Xue JY; Lito P
Cell; 2020 Nov; 183(4):850-859. PubMed ID: 33065029
[TBL] [Abstract][Full Text] [Related]
40. KRAS mutation in pancreatic cancer.
Luo J
Semin Oncol; 2021 Feb; 48(1):10-18. PubMed ID: 33676749
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
